Dr Barry received a PhD in Biostatistics from the University of North Carolina in Chapel Hill in 2006, and from 2007 to 2012 served as an Assistant Professor in the Department of Biostatistics and Bioinformatics at Duke University School of Medicine. Starting in 2009 he became the Director of the Bioinformatics Shared Resource for the Duke Cancer Institute. Dr Barry has also participation in the NCI's Clinical Trials Cooperative Group Program since 2007 as a faculty member of the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group B).
Statistical Methods in Cancer Research
Applied research interests are in clinical and translational research in cancer, undertaken through collaborations at Duke and Dana-Farber Cancer Institutes, and through participation in the NCI's Clinical Trials Cooperative Group Program since 2007 as a faculty member of the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group B). This includes biostatistical lead in multiple Phase II and III clinical trials and retrospective/prospective validations of tumor biomarkers.Methodologic research interests are various topics on the use of high-throughput technologies in clinical and translational research, including resampling-based methods for inference and multiple comparisons; Bayesian methods for discrimination; and the use of adaptive designs for Phase II trials in cancer with integral biomarkers.This work has appeared in over 50 co-authored peer-reviewed publications, and serves as the basis for invited lectures and workshops given to the American Society for Clinical Oncology (ASCO), Society for Clinical Trials (SCT), American Association for Cancer Research (AACR) and the European Organization for Research and Treatment of Cancer (EORTC).
Dana-Farber Cancer Institute450 Brookline AvenueCLSB 11005Boston MA, 02215Get Directions